Compare OMH & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | NSRX |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | Singapore | Israel |
| Employees | N/A | 7 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 32.2M |
| IPO Year | 2022 | N/A |
| Metric | OMH | NSRX |
|---|---|---|
| Price | $0.80 | $2.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 17.4K | ★ 79.9K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $1.98 |
| 52 Week High | $3.25 | $9.99 |
| Indicator | OMH | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 50.24 |
| Support Level | $0.75 | $2.04 |
| Resistance Level | $1.38 | $3.48 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.72 | 36.63 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.